Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Farallon Capital Management
AddedFeb 13, 2024
UpdatedJun 28, 2026
Farallon Capital Management

Farallon Capital Management

Operating

Farallon Capital: A global, multi-strategy American hedge fund, managing investments since 1986.

Location
San Francisco, CA, US
Founded
1986
Firm
Compare
Portfolio
Employees
Website

Investments

Beta Bionics
Beta Bionics

Total Raised

$293.5M

Rounds

8

Series D$100MAugust 2023
Series C$57MFebruary 2022
Forte Biosciences
Forte Biosciences
Public

Total Raised

$70.8M

Rounds

4

Post Ipo Debt$25MAugust 2023
Fog Pharmaceuticals
Fog Pharmaceuticals

Total Raised

$385.3M

Rounds

5

Series D$178MNovember 2022
Series C$107MJanuary 2021
Metagenomi
Metagenomi

Total Raised

$457M

Rounds

7

Series B$175MJanuary 2022
Freenome
Freenome

Total Raised

$1.1B

Rounds

8

Series D$300MDecember 2021
Series C$270MAugust 2020
Better Therapeutics
Better Therapeutics
Public

Total Raised

$150.5M

Rounds

7

Post Ipo Equity$70MOctober 2021
Inbrace
Inbrace

Total Raised

$217.6M

Rounds

7

Series D$102MSeptember 2021
Tango Therapeutics
Tango Therapeutics
Public

Total Raised

$351M

Rounds

5

Post Ipo Equity$186MAugust 2021
Genapsys
Genapsys
Acquired

Total Raised

$319M

Rounds

9

Series D$70MMay 2021
Biotheryx
Biotheryx
Public

Total Raised

$134.7M

Rounds

6

Series E$92MMay 2021
NeoGenomics Laboratories
NeoGenomics Laboratories
Acquired

Total Raised

$350.5M

Rounds

4

Post Ipo Equity$200MMay 2021
Affinia Therapeutics
Affinia Therapeutics

Total Raised

$170M

Rounds

2

Series B$110MMay 2021
Caribou Biosciences
Caribou Biosciences
Public

Total Raised

$317.7M

Rounds

9

Series C$115MMarch 2021
eGenesis
eGenesis

Total Raised

$265M

Rounds

4

Series C$125MMarch 2021
DarioHealth
DarioHealth
Public

Total Raised

$233.3M

Rounds

20

Post Ipo Equity$70MJanuary 2021
Beam Therapeutics
Beam Therapeutics
Public

Total Raised

$689M

Rounds

5

Post Ipo Equity$260MJanuary 2021
ImageneBio
ImageneBio
Public

Total Raised

$209M

Rounds

4

Series B$120MJanuary 2021
Arena Pharmaceuticals
Arena Pharmaceuticals
Acquired

Total Raised

$390.7M

Rounds

7

Post Ipo Equity$56MOctober 2020
Encoded Therapeutics
Encoded Therapeutics

Total Raised

$239.1M

Rounds

3

Series D$135MJuly 2020
VelosBio
VelosBio
Acquired

Total Raised

$202.7M

Rounds

3

Series B$137MJuly 2020
Pliant Therapeutics
Pliant Therapeutics
Public

Total Raised

$694.9M

Rounds

6

Series C$100.4MMarch 2020
Generation Bio
Generation Bio
Public

Total Raised

$536.4M

Rounds

6

Series C$110MJanuary 2020